IL316894A - Anti-tnfr2 antibodies and methods of use thereof - Google Patents

Anti-tnfr2 antibodies and methods of use thereof

Info

Publication number
IL316894A
IL316894A IL316894A IL31689424A IL316894A IL 316894 A IL316894 A IL 316894A IL 316894 A IL316894 A IL 316894A IL 31689424 A IL31689424 A IL 31689424A IL 316894 A IL316894 A IL 316894A
Authority
IL
Israel
Prior art keywords
methods
tnfr2 antibodies
tnfr2
antibodies
Prior art date
Application number
IL316894A
Other languages
Hebrew (he)
Inventor
Todd Douglas Ashworth
Yue Liu
Nicholas Andrew Marze
Virginie Mcmanus
Original Assignee
Pfizer
Todd Douglas Ashworth
Yue Liu
Nicholas Andrew Marze
Virginie Mcmanus
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer, Todd Douglas Ashworth, Yue Liu, Nicholas Andrew Marze, Virginie Mcmanus filed Critical Pfizer
Publication of IL316894A publication Critical patent/IL316894A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Transplantation (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL316894A 2022-05-26 2023-05-23 Anti-tnfr2 antibodies and methods of use thereof IL316894A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263365371P 2022-05-26 2022-05-26
US202363499860P 2023-05-03 2023-05-03
PCT/IB2023/055300 WO2023228082A1 (en) 2022-05-26 2023-05-23 Anti-tnfr2 antibodies and methods of use thereof

Publications (1)

Publication Number Publication Date
IL316894A true IL316894A (en) 2025-01-01

Family

ID=86776418

Family Applications (1)

Application Number Title Priority Date Filing Date
IL316894A IL316894A (en) 2022-05-26 2023-05-23 Anti-tnfr2 antibodies and methods of use thereof

Country Status (13)

Country Link
US (1) US20230406951A1 (en)
EP (1) EP4532546A1 (en)
JP (1) JP2025517490A (en)
KR (1) KR20250017237A (en)
CN (1) CN120380017A (en)
AU (1) AU2023276940A1 (en)
CA (1) CA3256751A1 (en)
CO (1) CO2024015993A2 (en)
IL (1) IL316894A (en)
MX (1) MX2024014579A (en)
PE (1) PE20250164A1 (en)
TW (1) TW202402789A (en)
WO (1) WO2023228082A1 (en)

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5624A (en) 1848-06-13 Fastening foe
US821A (en) 1838-06-30 blake
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
CA2323757C (en) 1998-04-02 2011-08-02 Genentech, Inc. Antibody variants and fragments thereof
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
JP2002522063A (en) 1998-08-17 2002-07-23 アブジェニックス インコーポレイテッド Generation of modified molecules with increased serum half-life
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
WO2006113546A2 (en) 2005-04-15 2006-10-26 Neogenix Oncology, Inc. Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
US7923538B2 (en) 2005-07-22 2011-04-12 Kyowa Hakko Kirin Co., Ltd Recombinant antibody composition
CA2676529C (en) 2007-01-24 2014-03-25 Kyowa Kirin Co., Ltd. Genetically recombinant antibody composition having enhanced effector activity
EP3494139B1 (en) * 2016-08-05 2022-01-12 F. Hoffmann-La Roche AG Multivalent and multiepitopic anitibodies having agonistic activity and methods of use
KR20210087466A (en) * 2018-11-01 2021-07-12 바이오인벤트 인터내셔날 에이비 Novel agonistic anti-TNFR2 antibody molecule
EP3880711A4 (en) * 2018-11-15 2022-12-28 The General Hospital Corporation AGONIST POLYPEPTIDES OF THE TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY
JP2024527576A (en) * 2021-07-07 2024-07-25 ハイファイバイオ(ホンコン)リミテッド Anti-TNFR2 antibodies and uses thereof

Also Published As

Publication number Publication date
CO2024015993A2 (en) 2024-12-09
KR20250017237A (en) 2025-02-04
JP2025517490A (en) 2025-06-05
PE20250164A1 (en) 2025-01-22
EP4532546A1 (en) 2025-04-09
US20230406951A1 (en) 2023-12-21
CN120380017A (en) 2025-07-25
WO2023228082A1 (en) 2023-11-30
MX2024014579A (en) 2025-01-09
CA3256751A1 (en) 2023-11-30
TW202402789A (en) 2024-01-16
AU2023276940A1 (en) 2024-12-12

Similar Documents

Publication Publication Date Title
GB202019709D0 (en) Anti-Coronavirus antibodies and methods of use
IL316368A (en) Anti-tl1a antibodies and methods of use thereof
HUE070287T2 (en) Anti-par-2 antibodies and methods of use thereof
IL315845A (en) Anti-dectin-1 antibodies and methods of use thereof
EP4089115A4 (en) ANTI-TIGIT ANTIBODIES AND METHOD OF USE
IL298668B1 (en) Anti-cd200r1 antibodies and methods of use thereof
IL319590A (en) Multispecific antibodies and methods of use thereof
IL316065A (en) Anti-cd28 antibodies and methods of use thereof
IL317690A (en) Anti-gpnmb antibodies and methods of use thereof
IL318694A (en) Anti-ccr8 antibodies and methods of use
IL308260A (en) Anti-tigit antibodies and methods of use thereof
IL316700A (en) Anti-bmp9 antibodies and methods of use thereof
IL311003A (en) Anti-her2 antibodies and methods of use thereof
IL325937A (en) AAV-delivered antibodies and methods of using them
IL318357A (en) Anti- il27r antibodies and methods of use thereof
IL321679A (en) Anti-ror-2 antibodies and methods of use
IL310551A (en) Osmr-specific monoclonal antibodies and methods of their use
AU2024374796A1 (en) Anti-migis-alpha antibodies and methods of use thereof
IL325840A (en) Bispecific PD-L1XCD28 antibodies and methods of using them
IL325837A (en) Bispecific PD-L1X4-1BB antibodies and methods of using them
GB202204813D0 (en) Human monoclonal antibodies and methods of use thereof
GB202204736D0 (en) Human monoclonal antibodies and methods of use thereof
CA3303930A1 (en) Anti-nectin-4 antibodies and methods of use thereof
CA3298139A1 (en) Aav-delivered antibodies and methods of use thereof
CA3292076A1 (en) Anti-toh1 antibodies and methods of use thereof